Your browser doesn't support javascript.
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.
Ruddy, Jake A; Boyarsky, Brian J; Werbel, William A; Bailey, Justin R; Karaba, Andrew H; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Durand, Christine M.
  • Ruddy JA; Department of Surgery.
  • Boyarsky BJ; Department of Surgery.
  • Werbel WA; Division of Infectious Diseases, Department of Medicine.
  • Bailey JR; Division of Infectious Diseases, Department of Medicine.
  • Karaba AH; Division of Infectious Diseases, Department of Medicine.
  • Garonzik-Wang JM; Department of Surgery.
  • Segev DL; Department of Surgery.
  • Durand CM; Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, USA.
AIDS ; 35(11): 1872-1874, 2021 09 01.
Article in English | MEDLINE | ID: covidwho-1358526
ABSTRACT
In this study of 12 people with HIV (PWH) who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor-binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4+ counts, and vaccine reactions were generally mild.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / HIV Infections / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: AIDS Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / HIV Infections / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: AIDS Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document Type: Article